60 Degrees Pharmaceuticals, Inc. (SXTPW) stock
SXTPWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SXTP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3033% below fair value
$0.03−0.00 (-0.38%)
Close on Oct 30, 2026Market cap $3.31MP/E –Yield –
60 Degrees Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
60 Degrees Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$8.61M. For fiscal 2025 it was -$7.76M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$7.76M | – |
| FY2024 | Dec 31, 2024 | -$9.72M | – |
| FY2023 | Dec 31, 2023 | -$5.15M | – |
| FY2022 | Dec 31, 2022 | -$1.75M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.27M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.09M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.92M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.33M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.61M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.91M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.07M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.12M | – |
| Q2 FY2024 | Jun 30, 2024 | -$4.19M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.34M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.89M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.52M | – |
| Q2 FY2023 | Jun 30, 2023 | -$788.00K | – |
| Q1 FY2023 | Mar 31, 2023 | -$950.66K | – |
| Q4 FY2022 | Dec 31, 2022 | -$684.70K | – |
| Q3 FY2022 | Sep 30, 2022 | -$215.12K | – |
| Q2 FY2022 | Jun 30, 2022 | -$686.92K | – |